India approves tirzepatide for weight loss and diabetes

Eli Lilly and Co. has received approval to import and sell a weight-loss medication in India. This drug, known as tirzepatide, will be marketed under the brand names Zepbound and Mounjaro. It is designed to treat type 2 diabetes and aid in weight loss. Tirzepatide works by mimicking hormones that help regulate insulin and appetite. It encourages the pancreas to produce more insulin, lowers sugar production in the liver, and helps people feel full with less food. Clinical trials show significant benefits, with patients experiencing lower blood sugar levels and weight loss compared to other treatments. Experts warn that while the drug can be beneficial, it must be used alongside diet and exercise. Side effects can include nausea, vomiting, and low blood sugar. It is not recommended for individuals with a history of certain thyroid cancers. The drug has been available in other countries since 2022, and doctors in India are eager for its arrival. However, medical supervision is crucial to prevent misuse. Eli Lilly plans to conduct further studies as required by Indian regulators before the drug is widely available.